This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: Astrazeneca Ab, Targacept, Inc.. Active years: 2012-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Södertälje, SE (2012)
- Sodertalje, SE (2014)
Company Filing History:
Years Active: 2012-2014
Title: **Per Olof Ryberg: Innovator in Pharmaceutical Science**
Introduction
Per Olof Ryberg, an accomplished inventor based in Södertälje, Sweden, has made significant contributions to the field of pharmaceutical science. With two patents to his name, Ryberg's innovative work focuses on the development of compounds that can effectively address various health challenges, including obesity.
Latest Patents
Ryberg's latest patents include groundbreaking research on substituted pyrazines as DGAT-1 inhibitors. His patent outlines DGAT-1 inhibitor compounds of formula (I), alongside pharmaceutically acceptable salts and pro-drugs. These compounds are crucial in creating pharmaceutical compositions aimed at treating conditions such as obesity. Another patent showcases a novel process for manufacturing the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile. This invention emphasizes the improvements in the synthesis of this compound and its salts, featuring new intermediates that facilitate large-scale production—an essential aspect for meeting increasing pharmaceutical demands.
Career Highlights
Ryberg is a key player at AstraZeneca AB, a leading global biopharmaceutical company. His expertise in innovative therapeutic solutions has been instrumental in advancing the company's mission to improve patient health worldwide. Throughout his career, Ryberg has exemplified dedication to research and development, showcasing his commitment to the field.
Collaborations
Collaborating with esteemed colleagues such as Alan Martin Birch and Roger John Butlin, Ryberg has participated in numerous projects that leverage their combined expertise. These collaborations have been vital in driving forward innovative solutions and enhancing the development of new pharmaceuticals.
Conclusion
Per Olof Ryberg stands out as a remarkable inventor whose work in developing effective pharmaceutical compounds is paving the way for advancements in treating obesity and other health conditions. His patents not only contribute to the scientific community but also reflect the potential for significant health improvements for individuals around the globe. As he continues his work with AstraZeneca AB, Ryberg's future endeavors are likely to yield further innovations in the pharmaceutical industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile